Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03359161|
Recruitment Status : Not yet recruiting
First Posted : December 1, 2017
Last Update Posted : December 1, 2017
|First Submitted Date ICMJE||November 27, 2017|
|First Posted Date ICMJE||December 1, 2017|
|Last Update Posted Date||December 1, 2017|
|Anticipated Start Date ICMJE||January 2018|
|Estimated Primary Completion Date||January 2019 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload|
|Official Title ICMJE||An Open Label, Descriptive Study to Evaluate the Clinical Utility of a Novel Formulation of Furosemide Delivered Subcutaneously in Patients Presenting With Early Signs of Fluid Overload|
|Brief Summary||This study will evaluate the usefulness of the subcutaneous administration of a new Lasix formulation. 20 patients will be evaluated in the first phase (pilot phase) and depending on the results, an additional 40 patients will be enrolled (Evaluation Phase). Patients with mild to moderate evidence of fluid overload who present to the cardiology service at St Elizabeth's Medical Center, Brighton, Massachusetts (SEMC) will be included in the study. Patients who qualify for thus study will be sent home with the sc2Wear™ Furosemide Infusor therapy for three days. This is a pump that patients place on their abdomen and it then delivers furosemide to the skin. Participants will be visited at home by a visiting nurse who will give them further teaching on the sc2Wear™ Furosemide Infusor. The visiting nurse will also be responsible for obtaining history (symptoms), physical examination (including inspecting the skin for adverse reactions related to the pump), and laboratory draws, supplementation of electrolytes as needed. Patients will be evaluated by the cardiology service of SEMC within 24 hours of the last dose of the sc2Wear™ Furosemide Infusor. If a patient is found to have satisfactorily responded but requires more therapy, an additional 4 days may be prescribed for total of seven consecutive treatments. If additional units are prescribed, patients will be evaluated by the cardiology service of SEMC within 24 hours of the last dose of the sc2Wear™ Furosemide infusion. Also an additionally, up to three-sc2Wear furosemide at home treatments may be used as authorized by the treating physician in case the patient experiences worsening heart failure within 30-days of enrollment (Rescue Treatment). Participants will be seen in clinic for follow up at 30±3 days after the start of the study for a post treatment.|
Investigational Product: Furosemide Injection, 8 mg/mL, (total dose =80 mg) administered subcutaneously by the sc2Wear Furosemide Infusor using a biphasic profile with 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours. Participants may be prescribed a total of 3 days initial treatment followed by an optional additional 4 days of sc2Wear furosemide treatment based on initial clinical response.
Study Objectives: 1.) Evaluate the clinical effect of sc2Wear furosemide Infusor in the in-home management of mild to moderate decompensated heart failure.
2.) Evaluate the safety and tolerability of sc2Wear furosemide Infusor in the in-home management of mild to moderate decompensated heart failure.
The cardiology service will screen patients with mild to moderate fluid overload. Patients who present with other serious or life threatening condition for which hospitalization would be indicated are excluded. Women of child bearing potential will be screened for pregnancy with a urine pregnancy test. Eligible participants will be educated on device preparation, placement, removal and care in accordance with the Instructions of Use Manual. The screening phase includes evaluation of the home situation to ascertain that sufficient support is or can be made available for at home treatment as an alternative to inpatient care. In appropriate settings, lay caregiver will also be trained.
Pilot Phase. Patients will be visited daily by Steward Home Care and Hospice for home health nursing services in accordance with standard procedures. Nursing services will include checking vitals, obtaining blood samples and evaluation for clinical improvement or worsening. The first visit will be performed within 24 hours after enrollment.
Study Procedures: The first sc2Wear Infusor will be prepared and placed on the patient as part of the training. The patient will go home with the sc2Wear furosemide Infusor in place on the abdomen to be activated upon arrival at home. Participants will be treated with the sc2Wear furosemide Infusor daily for 3 consecutive days at home. Participants will be evaluated by the cardiology service of SEMC within 24 hours after the 3rd dose of sc2Wear furosemide. If a patient was found to have responded satisfactorily but requires additional parenteral diuretics an additional 4 days may be prescribed for a total of 7 consecutive treatments. If additional units are prescribed patients are to be evaluated the cardiology service of SEMC within 24 hours after the last dose of sc2Wear furosemide Infusor. If the subject requires further parenteral diuresis after the 7 days of at home treatment, they will be converted to usual care at that time, which may require inpatient care. Participants will be instructed to record daily morning weights during and after treatment until the second post treatment evaluation. Interim clinic visits and laboratory assessments may be required based on clinical considerations.
The following parameters will be studied at Baseline and follow-up treatment visits.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2
|Study Design ICMJE||Intervention Model: Single Group Assignment
Intervention Model Description:
This is a prospective, open-label, descriptive two-phase study to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration. Participants with mild to moderate signs of fluid overload will be included in the study. The study involves at home treatment with a novel formulation of subcutaneous furosemide. In the Pilot Phase (20 patients) will undergo 3 days of at home treatment for fluid overload. If determined to require more, will undergo an extra 4 days of treatment. The Investigator and her team will review the results for the first cohort and depending on the results will proceed to the Evaluation phase (40 patients).Masking: None (Open Label)
Primary Purpose: Treatment
|Condition ICMJE||Heart Failure|
|Intervention ICMJE||Combination Product: sc2Wear Furosemide Infusor
Subcutaneous furosemide for the treatment of fluid overload
|Study Arms||Experimental: In-Home Subcutaneous Furosemide Treatment ARm
Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
Intervention: Combination Product: sc2Wear Furosemide Infusor
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Not yet recruiting|
|Estimated Enrollment ICMJE||60|
|Estimated Completion Date||June 2019|
|Estimated Primary Completion Date||January 2019 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
Age≥ 18 years Symptomatic and chronic heart failure (NYHA Class II and III). Patients on guideline directed medical therapy 90 days prior to enrollment. Adequate home environment for at-home treatment. Presenting or referred to the ER or clinic because of evidence of worsening heart failure with fluid overload (decompensation).
A modification in oral diuretics is not clinically appropriate as deemed by the investigator.
Estimated excess fluid weight of 4 lbs. or more from euvolemic state. Participant able to give informed consent for participation in trial. Agreeing to sign informed consent and HIPAA authorization.
Understanding and willing to comply with the protocols of the trial
ACC/AHA Stage D heart failure or patients requiring IV inotrope therapy. Massive volume overload (e.g., >20 lbs. of estimated fluid weight) or anasarca. Suspected high risk clinical instability with outpatient treatment. Pregnant females or women of child-bearing age who are not willing to use an adequate form of contraception.
Chronic Obstructive Pulmonary Disease (COPD) moderate or worse: forced expiratory volume at one second (FEV1): Forced vital capacity (FCV) ratio <0.7 and FEV1 <60 percent predicted.
Rapid atrial fibrillation (HR >100bpm). Hypoxia (resting O2 saturation <90%). Hypotension (systolic blood pressure < 90 mmHg) Uncontrolled diabetes mellitus (glucose >300mg/ dL) Advanced renal disease (eGFR < 30mL/min/1.73m2). Acute coronary syndrome. Serum potassium K <3.2 mmol/L or > 5.5mmol/L. On experimental medication or currently participating in an interventional cardiovascular research study, other than an observational or registry study.
Having received intravenous furosemide within 24 hours prior to enrollment. Urinary tract abnormality or disorder interfering with urination. Allergy to the active and inactive ingredients of the study medication.
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Listed Location Countries ICMJE||Not Provided|
|Removed Location Countries|
|NCT Number ICMJE||NCT03359161|
|Other Study ID Numbers ICMJE||Clinical Protocol Version 4.0|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||
|IPD Sharing Statement||
|Responsible Party||Lana Tsao, Steward St. Elizabeth's Medical Center of Boston, Inc.|
|Study Sponsor ICMJE||Steward St. Elizabeth's Medical Center of Boston, Inc.|
|Collaborators ICMJE||Not Provided|
|PRS Account||Steward St. Elizabeth's Medical Center of Boston, Inc.|
|Verification Date||November 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP